Watchlist Price Alert

EyePoint Pharmaceuticals ... (EYPT)

NASDAQ: EYPT · Real-Time Price · USD

6.12

0.40 (6.99%)

At close: May 16, 2025, 3:59 PM

6.10

-0.33%

After-hours: May 16, 2025, 05:14 PM EDT

6.99% (1D)

Bid	5.87
Market Cap	421.13M
Revenue (ttm)	56.04M
Net Income (ttm)	-146.78M
EPS (ttm)	-2.32
PE Ratio (ttm)	-2.64
Forward PE	-1.99
Analyst	Buy

Ask	6.25
Volume	942,437
Avg. Volume (20D)	785,662
Open	5.82
Previous Close	5.72
Day's Range	5.73 - 6.14
52-Week Range	3.91 - 13.99
Beta	1.60

About EYPT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EYPT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EYPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

EyePoint Pharmaceuticals has released their quartely earnings on May 7, 2025:

Revenue of $24.45M exceeds estimates by $16.36M, with 109.29% YoY growth.

EPS of -0.65 misses estimates by -0.10, with -18.18% YoY decline.

Why Price Moved

3 months ago

+2.36%

EyePoint Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

6 months ago

+27.58%

EyePoiint Pharmaceuticals shares are trading higher after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.

News

1 week ago · seekingalpha.com

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker ...

1 week ago · zacks.com

EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wal...

1 week ago · zacks.com

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.

2 months ago · seekingalpha.com

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - ...

2 months ago · zacks.com

EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for EyePoint Pharmaceuticals (EYPT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compa...

2 months ago · zacks.com

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.33 per share a year ago.